Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02810457 · ClinicalTrials.gov registry record · Phase 3

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Centus Biotherapeutics Limited.

Completed
Registry status
Phase 3
Development phase
731
Enrollment target
20
Study locations

NCT02810457: Completed Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Centus Biotherapeutics Limited.

NCT02810457 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that has completed, run by Centus Biotherapeutics Limited. The registered enrollment target is 731 participants, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02810457, a Phase 3 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Centus Biotherapeutics Limited.

COMPLETED
Registry status
Phase 3
Development phase
731 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

Primary Outcome

The primary variable in this study was ORR, defined as the proportion of patients with a BOR of CR or PR (by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)). A BOR was defined as the best response (in the order of CR, PR, stable disease (SD), no evidence of disease (NED), progressive disease (PD), and not evaluable (NE)) among all post-baseline disease assessments that occurred until progression, or last evaluable assessment in the absence of progression prior to the init

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG FKB238 (bevacizumab)
  • DRUG Avastin (bevacizumab)

Study Locations (20)

Ohio

  • Research Site 7805 - Hematology & Oncology Associates, Inc. - Canton
  • Research Site 7801 - Gabrail Cancer Center - Canton
  • Research Site 7804 - Tri-County Hematology & Oncology Associates, Inc. - Massillon

California

  • Research Site 7814 - Compassionate Care Research Group - Fountain Valley
  • Research Site 7811 - Innovative Clinical Research Institute - Whittier

Illinois

  • Research Site 7812 - Joliet Oncology-Hematology Associates, Ltd. - Joliet
  • Research Site 7810 - Edward H. Kaplan, MD and Associates - Skokie

Minsk Oblast

  • Research Site 8501 - Lyasny
  • Research Site 8504 - Minsk

Other

  • Research Site 8606 - Banja Luka
  • Research Site 8602 - Mostar

Florida

  • Research Site 7803 - 21st Century Oncology - Jacksonville

North Dakota

  • Research Site 7813 - Trinity Cancer Care Center - Minot

Texas

  • Research Site 7809 - Millennium Oncology - Houston

Trial Details

FieldValue
Enrollment Target 731 participants
Start Date 2016-09-07
Est. Completion 2022-01-26
Phase Phase 3
Centus Biotherapeutics Limited

1 total trials

What the finished NCT02810457 record still lists

NCT02810457 is an interventional study that assigns participants to a tested intervention. The registered 731 participants enrollment target is mid-sized for trials with a published cap, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (130% higher).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT02810457 names 20 study sites across 14 states, led by Ohio, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT02810457 about?

NCT02810457 is a clinical study titled "Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer". The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

What is the current status of trial NCT02810457?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 731 participants. The study started on 2016-09-07. Estimated completion is 2022-01-26.

What conditions does trial NCT02810457 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT02810457?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), FKB238 (bevacizumab) (DRUG), Avastin (bevacizumab) (DRUG).

Who is sponsoring clinical trial NCT02810457?

This trial is sponsored by Centus Biotherapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02810457 being conducted?

This trial has 20 study locations across California, Florida, Illinois, North Dakota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02810457's enrollment target sits among peer trials

731 13th of 130 higher than 118 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03232918 · 730 participants · Phase 4

    Oxytocin and Fetal Heart Rate Changes

  • NCT05548283 · 730 participants · Phase 4

    Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

  • NCT07312162 · 730 participants

    Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

  • NCT06216301 · 734 participants · Phase 3

    LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02810457, the US trial registry maintained by the National Library of Medicine. NCT02810457 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.